Protocol Ledger

NCT04856982 · Phase III · ACTIVE NOT RECRUITING

Study to Learn If Tofersen (BIIB067) Can Delay ALS Symptoms and About Its Safety in Adults With a SOD1 Gene Mutation Who Have Not Yet Developed ALS Symptoms

Interventional Phase III clinical trial protocol NCT04856982 sponsored by Biogen in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-05-17 Enrollment: 158 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04856982
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)158 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04856982
Protocol FieldVerified Registry Value
NCT IdentifierNCT04856982
Consolidated Lead SponsorBiogen
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment158 participants (ACTUAL)
Registered Start Date2021-05-17
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Biogen across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI